Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-GPC2-CAR T cells

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-2 (GPC2), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-GPC2-CAR T cells specifically target and bind to GPC2-expressing tumor cells, resulting in tumor cell lysis. GPC2, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-GPC2 CAR autologous T cells
anti-GPC2-CAR autologous T lymphocytes
autologous anti-GPC2 CAR-T cells
autologous glypican-2-specific CAR T cells
autologous GPC2 CAR T cells
GPC2-targeted CAR autologous T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search